ArticleEJVES vascular forum2026
Early Endovenous Thermal Ablation With Concomitant Anticoagulation in Chronic Venous Insufficiency Complicated by Superficial Venous Thrombosis: A Retrospective Observational Study.
Article in EJVES vascular forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Whether endovenous thermal ablation (EVTA) can be performed soon after the diagnosis of superficial venous thrombosis (SVT) in patients with chronic venous insufficiency (CVI) remains uncertain. This study assessed the safety and clinical benefit of early EVTA performed under anticoagulation. Method: Consecutive CVI patients with acute SVT (symptom onset ≤14 days) who underwent endovenous laser ablation (EVLA), radiofrequency ablation (RFA), or endovenous microwave ablation (EMA) between January 2022 and March 2025 were identified. All received peri-procedural anticoagulation. Co-primary endpoints were technical success (first post-procedural duplex) and clinical improvement (change in Venous Clinical Severity Score [VCSS] to six months). Secondary endpoints included immediate pain relief (numerical rating scale [NRS] at rest and movement to discharge), Venous Insufficiency Epidemiological and Economic Study-Quality of Life (VEINES-QoL) change to six months, and complications (including deep vein thrombosis [DVT] and pulmonary embolism [PE]) and recurrence. Results: The study analysed 255 patients (262 limbs) with a median follow up of 14 months. Mean procedure duration was 54.3 ± 22.1 minutes. Complications were uncommon: DVT 1.2% (3 of 262), minor bleeding 0.78% (2 of 255); there was no PE, re-operation, or infection. Pain improved substantially (NRS decreased by 2.59 points at rest and 4.15 points with movement). Clinical severity and QoL also improved (VCSS decreased by 5.73 ± 1.78 points; VEINES-QoL increased by 12.87 ± 1.92 points). Outcomes and complication rates did not differ between EVLA, RFA, and EMA. Conclusion: In this cohort, early EVTA under anticoagulation appeared feasible and was associated with low thrombotic and bleeding complication rates and clinically meaningful improvements in pain, clinical severity, and quality of life. Given the non-controlled design, findings should be interpreted as hypothesis generating and warrant confirmation in comparative prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.